FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2624213194> ?p ?o ?g. }

• W2624213194 abstract "HomeCirculationVol. 135, No. 23Letter by Siasos et al Regarding Article, “Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Siasos et al Regarding Article, “Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease” Gerasimos Siasos, MD, PhD, Demetrios Moris, MD, PhD and Dimitris Tousoulis, MD, PhD Gerasimos SiasosGerasimos Siasos From First Department of Cardiology, Hippokration General Hospital (G.S., D.T.), and First Department of Surgery, Laikon General Hospital (D.M.), National and Kapodistrian University of Athens, School of Medicine, Greece. Search for more papers by this author , Demetrios MorisDemetrios Moris From First Department of Cardiology, Hippokration General Hospital (G.S., D.T.), and First Department of Surgery, Laikon General Hospital (D.M.), National and Kapodistrian University of Athens, School of Medicine, Greece. Search for more papers by this author and Dimitris TousoulisDimitris Tousoulis From First Department of Cardiology, Hippokration General Hospital (G.S., D.T.), and First Department of Surgery, Laikon General Hospital (D.M.), National and Kapodistrian University of Athens, School of Medicine, Greece. Search for more papers by this author Originally published6 Jun 2017https://doi.org/10.1161/CIRCULATIONAHA.116.026927Circulation. 2017;135:e1107–e1108To the Editor:We read with great interest the work by Jones et al1 comparing the efficiency of P2Y12 receptor inhibitors (clopidogrel versus ticagrelor) as antithrombotic regimens for long-term management in patients with symptomatic peripheral artery disease. Current knowledge in the field demonstrates that in patients with symptomatic peripheral artery disease with a history of limb revascularization, the optimal antithrombotic regimen for long-term management remains unknown.2 The authors found that ticagrelor did not reduce the primary composite end point of cardiovascular mortality, myocardial infarction, or ischemic stroke compared with clopidogrel in patients with peripheral artery disease and a history of lower extremity revascularization.1Although these findings are interesting, it is not clear whether other factors involved in platelet reactivity and cardiovascular outcome were evaluated in depth. As is already highlighted in the literature, individual platelet response to antiplatelet therapy depends on a variety of factors, including genetic background, cellular interactions (accelerated platelet turnover, reduced CYP3A metabolic activity, increased adenosine diphosphate exposure, upregulation of P2Y12 pathways), clinical factors (age, diabetes mellitus, smoking, left ventricular ejection function, body mass index, vascular function, creatinine clearance, inflammation, comorbidities, underdosing, poor absorption, concurrent medication), and geographic origin.3,4 As the authors demonstrated in Tables 1 and 2, many of these factors were adequately randomized among medication groups in the revascularization arm of the study. It is not clear whether patients in the ankle-brachial index arm and patients without previous limb revascularization had any difference in the factors mentioned above.Despite the fact that the authors explained that all patients included in this trial underwent genotype testing for CYP2C19 and those with 2 loss-of-function alleles were excluded from the study, coexisting polymorphisms may affect platelet response variability and clinical outcome more than single polymorphisms. Thus, the individual genomic profile should include not only CYP2C19 polymorphisms but also all the polymorphic genes involved in the pharmacokinetic and pharmacodynamic response to P2Y12 receptor inhibitor treatment. Moreover, a comparison among carriers of 1 reduced-function allele (CYP2C19*1/*2, heterozygotes) and noncarriers (CYP2C19*1/*1, wild-type homozygotes) would be of great clinical importance because studies of acute coronary disease have shown that the carriers of at least 1 CYP2C19*2 loss-of-function allele had marginally higher platelet reactivity and cardiovascular events compared with noncarriers.5 In addition, the authors did not evaluate the aspirin resistance rates in their population, which would be of interest because in both arms >70% of the patients were on aspirin. Polymorphisms in cyclooxygenase-1 and -2 genes should also be evaluated in the framework of aspirin resistance, which could be translated into clinical aspirin resistance and cardiovascular risk.The precise definition of multiple genetic, cellular, and clinical determinants influencing platelet reactivity will lead to an individualized, more effective adjustment of antiplatelet treatment in peripheral artery disease and to a reduction in cardiovascular and limb-related adverse events.Gerasimos Siasos, MD, PhDDemetrios Moris, MD, PhDDimitris Tousoulis, MD, PhDDisclosuresNone.FootnotesCirculation is available at http://circ.ahajournals.org.References1. Jones WS, Baumgartner I, Hiatt WR, Heizer G, Conte MS, White CJ, Berger JS, Held P, Katona BG, Mahaffey KW, Norgren L, Blomster J, Millegård M, Reist C, Patel MR, Fowkes FG; International Steering Committee and Investigators of the EUCLID Trial. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease.Circulation. 2017; 135:241–250. doi: 10.1161/CIRCULATIONAHA.116.025880.LinkGoogle Scholar2. Klonaris C, Patelis N, Drebes A, Matheiken S, Liakakos T. Antiplatelet treatment in peripheral arterial disease: the role of novel antiplatelet agents.Curr Pharm Des. 2016; 22:4610–4616.CrossrefMedlineGoogle Scholar3. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel.N Engl J Med. 2009; 360:354–362. doi: 10.1056/NEJMoa0809171.CrossrefMedlineGoogle Scholar4. Siasos G, Oikonomou E, Zaromitidou M, Kioufis S, Kokkou E, Mourouzis K, Vlasis K, Vavuranakis M, Stone PH, Papavassiliou AG, Tousoulis D. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.Atherosclerosis. 2015; 242:102–108. doi: 10.1016/j.atherosclerosis.2015.07.009.CrossrefMedlineGoogle Scholar5. Tousoulis D, Siasos G, Zaromitidou M, Oikonomou E, Maniatis K, Kioufis S, Kokkou E, Papavassiliou AG, Stefanadis C. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.Int J Cardiol. 2013; 168:1594–1596. doi: 10.1016/j.ijcard.2013.01.040.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails June 6, 2017Vol 135, Issue 23 Advertisement Article InformationMetrics © 2017 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.116.026927PMID: 28584035 Originally publishedJune 6, 2017 PDF download Advertisement" @default.
• W2624213194 created "2017-06-15" @default.
• W2624213194 creator A5003554644 @default.
• W2624213194 creator A5034212396 @default.
• W2624213194 creator A5072293972 @default.
• W2624213194 date "2017-06-06" @default.
• W2624213194 modified "2023-09-26" @default.
• W2624213194 title "Letter by Siasos et al Regarding Article, “Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease”" @default.
• W2624213194 cites W1985059672 @default.
• W2624213194 cites W2030349814 @default.
• W2624213194 cites W2132005924 @default.
• W2624213194 cites W2411687366 @default.
• W2624213194 cites W2556919357 @default.
• W2624213194 doi "https://doi.org/10.1161/circulationaha.116.026927" @default.
• W2624213194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28584035" @default.
• W2624213194 hasPublicationYear "2017" @default.
• W2624213194 type Work @default.
• W2624213194 sameAs 2624213194 @default.
• W2624213194 citedByCount "0" @default.
• W2624213194 crossrefType "journal-article" @default.
• W2624213194 hasAuthorship W2624213194A5003554644 @default.
• W2624213194 hasAuthorship W2624213194A5034212396 @default.
• W2624213194 hasAuthorship W2624213194A5072293972 @default.
• W2624213194 hasBestOaLocation W26242131941 @default.
• W2624213194 hasConcept C126322002 @default.
• W2624213194 hasConcept C164705383 @default.
• W2624213194 hasConcept C2777466421 @default.
• W2624213194 hasConcept C2777628954 @default.
• W2624213194 hasConcept C2777849778 @default.
• W2624213194 hasConcept C2780890252 @default.
• W2624213194 hasConcept C3018348675 @default.
• W2624213194 hasConcept C71924100 @default.
• W2624213194 hasConceptScore W2624213194C126322002 @default.
• W2624213194 hasConceptScore W2624213194C164705383 @default.
• W2624213194 hasConceptScore W2624213194C2777466421 @default.
• W2624213194 hasConceptScore W2624213194C2777628954 @default.
• W2624213194 hasConceptScore W2624213194C2777849778 @default.
• W2624213194 hasConceptScore W2624213194C2780890252 @default.
• W2624213194 hasConceptScore W2624213194C3018348675 @default.
• W2624213194 hasConceptScore W2624213194C71924100 @default.
• W2624213194 hasIssue "23" @default.
• W2624213194 hasLocation W26242131941 @default.
• W2624213194 hasLocation W26242131942 @default.
• W2624213194 hasOpenAccess W2624213194 @default.
• W2624213194 hasPrimaryLocation W26242131941 @default.
• W2624213194 hasRelatedWork W2040341204 @default.
• W2624213194 hasRelatedWork W2792806141 @default.
• W2624213194 hasRelatedWork W2810359251 @default.
• W2624213194 hasRelatedWork W2891656742 @default.
• W2624213194 hasRelatedWork W3034373083 @default.
• W2624213194 hasRelatedWork W3063669788 @default.
• W2624213194 hasRelatedWork W3134665543 @default.
• W2624213194 hasRelatedWork W3135788989 @default.
• W2624213194 hasRelatedWork W3159167316 @default.
• W2624213194 hasRelatedWork W4293441875 @default.
• W2624213194 hasVolume "135" @default.
• W2624213194 isParatext "false" @default.
• W2624213194 isRetracted "false" @default.
• W2624213194 magId "2624213194" @default.
• W2624213194 workType "article" @default.